Skip to main content
Journal cover image

GRK2 as a novel gene therapy target in heart failure.

Publication ,  Journal Article
Rengo, G; Lymperopoulos, A; Leosco, D; Koch, WJ
Published in: J Mol Cell Cardiol
May 2011

Despite significant advances in pharmacological and clinical treatment, heart failure (HF) remains a leading cause of morbidity and mortality worldwide. HF is a chronic and progressive clinical syndrome characterized by a reduction in left ventricular (LV) ejection fraction and adverse remodeling of the myocardium. The past several years have seen remarkable progress using animal models in unraveling the cellular and molecular mechanisms underlying HF pathogenesis and progression. These studies have revealed potentially novel therapeutic targets/strategies. The application of cardiac gene transfer, which allows for the manipulation of targets in cardiomyocytes, appears to be a promising therapeutic tool in HF. β-adrenergic receptor (βAR) dysfunction represents a hallmark abnormality of chronic HF, and increased G protein-coupled receptor kinase 2 (GRK2) levels/activity in failing myocardium is among these alterations. In the past 15years, several animal studies have shown that expression of a peptide inhibitor of GRK2 (βARKct) can improve the contractile function of failing myocardium including promoting reverse remodeling of the LV. Therefore, data support the use of the βARKct as a promising candidate for therapeutic application in human HF. Importantly, recent studies in cardiac-specific GRK2 knockout mice have corroborated GRK2 being pathological in failing myocytes. The purpose of this review is to discuss: 1) the alterations of βAR signaling that occur in HF, 2) the evidence from transgenic mouse studies investigating the impact of GRK2 manipulation in failing myocardium, 3) the therapeutic efficacy of in vivo βARKct gene therapy in HF, and 4) the intriguing possibility of lowering HF-related sympathetic nervous system hyperactivity by inhibiting GRK2 activity in the adrenal gland. This article is part of a Special Section entitled "Special Section: Cardiovascular Gene Therapy".

Duke Scholars

Published In

J Mol Cell Cardiol

DOI

EISSN

1095-8584

Publication Date

May 2011

Volume

50

Issue

5

Start / End Page

785 / 792

Location

England

Related Subject Headings

  • Models, Biological
  • Humans
  • Heart Failure
  • Genetic Therapy
  • G-Protein-Coupled Receptor Kinase 2
  • Cardiovascular System & Hematology
  • Animals
  • 3208 Medical physiology
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rengo, G., Lymperopoulos, A., Leosco, D., & Koch, W. J. (2011). GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol, 50(5), 785–792. https://doi.org/10.1016/j.yjmcc.2010.08.014
Rengo, Giuseppe, Anastasios Lymperopoulos, Dario Leosco, and Walter J. Koch. “GRK2 as a novel gene therapy target in heart failure.J Mol Cell Cardiol 50, no. 5 (May 2011): 785–92. https://doi.org/10.1016/j.yjmcc.2010.08.014.
Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol. 2011 May;50(5):785–92.
Rengo, Giuseppe, et al. “GRK2 as a novel gene therapy target in heart failure.J Mol Cell Cardiol, vol. 50, no. 5, May 2011, pp. 785–92. Pubmed, doi:10.1016/j.yjmcc.2010.08.014.
Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol. 2011 May;50(5):785–792.
Journal cover image

Published In

J Mol Cell Cardiol

DOI

EISSN

1095-8584

Publication Date

May 2011

Volume

50

Issue

5

Start / End Page

785 / 792

Location

England

Related Subject Headings

  • Models, Biological
  • Humans
  • Heart Failure
  • Genetic Therapy
  • G-Protein-Coupled Receptor Kinase 2
  • Cardiovascular System & Hematology
  • Animals
  • 3208 Medical physiology
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology